Loading…
NKTX
Nkarta, Inc.
NASDAQ· Healthcare· Biotechnology· CUSIP 65487U108
$1.80-6.74%Price as of Oct 17, 12:22 UTC · updated once a day, after the close
At a glance
Nkarta, Inc. (NKTX) is listed on NASDAQ and classified in Biotechnology, part of the Healthcare sector. It is headquartered in South San Francisco, United States and has 106 employees. The company is worth $128.92M. Revenue was $0 in fiscal 2025. It reported a net loss of $104.08M. The share price is 51.6% below its 52-week high of $3.72. 6 of the 38 superinvestors we track held it at the end of Q2 2026. The largest position belongs to Ken Griffin (Citadel Advisors), at $6.15M. In that quarter, 2 of them opened or added to the position and 1 reduced it. No open-market insider trades in it were filed over the last 30 days.
Written from the data on this page: SEC filings (13F, Form 4, annual reports) and market prices.
Key metrics
- Market cap
- $128.92M
- P/E
- —
- Forward P/E
- —
- P/B
- 0.5x
- Dividend yield
- 0.00%
- Payout
- —
- EPS
- -$1.58
- ROE
- -38.76%
- Profit margin
- 0.00%
- Revenue growth
- —
- Beta
- 0.94
- 52-week high
- $3.72
- 52-week low
- $1.70
History
Year by year, from the annual reports; dividends from the payments themselves.
Bars are year-end balances; lines are what happened during the year.
Investors holding this
Major managers that reported this stock in their latest 13F.
Price over time
▼ -88.7% over 5Y.
today you would have $114.80▼ -88.5%
Dividends reinvested, splits accounted for. Past prices say what happened, not what will.
Indicators, year by year
The last 6 closed years, each at that year’s closing price and reported numbers.
| Indicator | Median | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|---|
| Year-end price | $1.85 | $2.49 | $6.60 | $5.99 | $15.35 | $61.47 | |
| P/B | 1.0x | 0.4x | 0.4x | 1.2x | 0.8x | 2.0x | 6.3x |
| EPS | -$1.41 | -$1.60 | -$2.40 | -$2.61 | -$2.62 | -$5.44 | |
| ROE | -31.95% | -33.33% | -26.67% |
Others in the same sector
Companies of similar size in Healthcare, for comparison. The columns are the same ones above, in the same order.
| Stock | Price | P/E | P/B | Dividend yield | ROE | Market cap |
|---|---|---|---|---|---|---|
| ANTXAN2 Therapeutics, Inc. | $3.38 | — | 1.6x | 0.00% | -50.12% | $127.55M |
| HCATHealth Catalyst, Inc. | $1.74 | — | 1.3x | 0.00% | -118.12% | $130.95M |
| RNAAtrium Therapeutics, Inc. | $7.67 | — | 0.6x | 0.00% | — | $131.2M |
| ORGOOrganogenesis Holdings Inc. | $1.03 |
About the company
- 106
- South San Francisco, United States